Page last updated: 2024-11-05

benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide: Proposed cholinesterase inhibitor. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9820
CHEMBL ID464538
MeSH IDM0003118

Synonyms (19)

Synonym
4,4'-(3-oxopentane-1,5-diyl)bis[n,n-dimethyl-n-(prop-2-en-1-yl)anilinium] dibromide
1,5-bis(4-allyldimethylammoniumphenyl)pentan-3-one dibromide
chembl464538 ,
402-40-4
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl)-, dibromide
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide
bw 284 c 51
bw-28c51
4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenylbenzenaminium) dibromide
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-, dibromide
1,5-bis(4-allyldimethylammoniumphenyl)pentan-3-one, dibromide
FT-0606944
4,4'-(3-oxo-1,5-pentanediyl)bis[n,n-dimethyl-n-2-propenylbenzenaminium] dibromide
[4-[5-[4-(dimethyl-prop-2-enyl-ammonio)-phenyl]-3-oxo-pentyl]phenyl]-dimethyl-prop-2-enyl-azanium dibromide
1,5-bis(4-allyldimethyl-ammoniumphenyl)pentan-3-one dibromide
[4-[5-[4-[dimethyl(prop-2-enyl)azaniumyl]phenyl]-3-oxopentyl]phenyl]-dimethyl-prop-2-enylazanium;dibromide
1,5-bis[4-(allyldimethylammonium)phenyl]pentan-3-one dibromide
DTXSID90960624
1,5-bis(4-allyldimethyl-ammoniumphenyl)pentan-3-onedibromide

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The effect of acetylcholine is also significantly potentiated by pretreatment with 6-hydroxydopamine or denervation, but not by reserpine, while the dose-response curve for carbachol is not affected by the specific cholinesterase inhibitor BW 284 C51, denervation or 6-hydroxydopamine."( Uptake and release of catecholamines in sympathetic nerve fibers in the spleen of the cod, Gadus morhua.
Holmgren, S; Nilsson, S, 1976
)
0.26
" BW284c51 blockade was non-competitive and voltage-dependent, although it also affected the n(H) of the dose-response curve."( Diverse inhibitory actions of quaternary ammonium cholinesterase inhibitors on Torpedo nicotinic ACh receptors transplanted to Xenopus oocytes.
Ivorra, I; Morales, A; Olivera-Bravo, S, 2007
)
0.34
" In the presence of higher lidocaine doses, nicotinic receptors were blocked both at positive and negative potentials, acetylcholine dose-response curve shifted to the right and lidocaine pre-application, before its co-application with acetylcholine, enhanced the current inhibition, indicating all together that lidocaine also blocked resting receptors; besides, it increased the current decay rate."( Multiple inhibitory actions of lidocaine on Torpedo nicotinic acetylcholine receptors transplanted to Xenopus oocytes.
Alberola-Die, A; González-Ros, JM; Ivorra, I; Martinez-Pinna, J; Morales, A, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)0.03650.00000.94539.9400AID386741; AID398849
CholinesteraseHomo sapiens (human)IC50 (µMol)354.00000.00001.559910.0000AID551379
CholinesteraseHomo sapiens (human)Ki0.05000.00001.51739.7300AID551382
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)0.02760.00000.933210.0000AID1058694; AID262754; AID551378; AID569588; AID589521
AcetylcholinesteraseHomo sapiens (human)Ki0.12380.00001.27869.7300AID1058689; AID1058691; AID407780; AID551381; AID569591; AID569592; AID589525; AID589526
Acetylcholinesterase Bos taurus (cattle)Ki0.05710.00130.08930.7940AID404439
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesterase Bos taurus (cattle)
protein bindingAcetylcholinesterase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesterase Bos taurus (cattle)
side of membraneAcetylcholinesterase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID589521Inhibition of human erythrocyte recombinant AChE by modified Ellman's method2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
AID1140645Displacement of propidium iodide from AchE in bovine erythrocytes at 3 uM after 15 mins by fluorescence microplate reader analysis2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID469402Displacement of propidium iodide from AChE peripheral anionic site at 3 uM2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID589525Inhibition of human erythrocytes recombinant AChE assessed as dissociation constant for enzyme-inhibitor complex2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
AID469400Displacement of propidium iodide from AChE peripheral anionic site at 0.3 uM2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID589523Inhibition of human plasmatic BChE by modified Ellman's method2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
AID569592Dissociation constant for enzyme-inhibitor-substrate complex of human recombinant AChE by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
AID1058694Inhibition of human recombinant AChE after 5 mins by Ellman's method2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors.
AID386739Inhibition of human plasma BuchE by Ellman's method2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.
AID1058692Selectivity index, ratio of IC50 for human plasmatic BChE to IC50 for human recombinant AChE2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors.
AID407780Inhibition of human AChE2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID569591Dissociation constant for enzyme-inhibitor complex of human recombinant AChE by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
AID551379Inhibition of human recombinant BChE2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.
AID386741Inhibition of electric eel AchE by Ellman's method2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.
AID1140644Displacement of propidium iodide from AchE in bovine erythrocytes at 1 uM after 15 mins by fluorescence microplate reader analysis2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID589526Inhibition of human erythrocytes recombinant AChE assessed as dissociation constant for enzyme-inhibitor-substrate complex2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
AID569589Inhibition of human plasmatic BChE by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
AID551381Inhibition of human recombinant AChE assessed as dissociation constant for enzyme-inhibitor complex by Lineweaver-Burk plot2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID404439Inhibition of bovine AChE2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID551378Inhibition of human recombinant AChE2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.
AID569588Inhibition of human recombinant AChE by Lineweaver-Burk plot analysis2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
AID469401Displacement of propidium iodide from AChE peripheral anionic site at 1 uM2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1058691Non competitive inhibition of human recombinant AChE using ATChCl as substrate by Lineweaver-Burk plot analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors.
AID551382Inhibition of human recombinant AChE assessed as dissociation constant for enzyme-inhibitor-substrate complex by Lineweaver-Burk plot2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.
AID1058689Inhibition of human recombinant AChE by Lineweaver-Burk plot analysis2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors.
AID482864Displacement of propidium iodide from AChE in bovine erythrocytes at 1 mM after 15 mins by fluorescence plate reader2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID569590Selectivity ratio of IC50 for human plasmatic BChE to IC50 for human recombinant AChE2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment.
AID1140643Displacement of propidium iodide from AchE in bovine erythrocytes at 0.3 uM after 15 mins by fluorescence microplate reader analysis2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
AID1140641Inhibition of human serum BuChE using butyrylthiocholine as substrate incubated for 5 mins prior to substrate addition measured after 5 mins by Ellman method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
AID262755Anticholinesterase activity against human plasma BChE2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
AID1058693Inhibition of human plasmatic BChE after 5 mins by Ellman's method2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Preparation, in vitro evaluation and molecular modelling of pyridinium-quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID398849Inhibition of electric eel AChE by Ellman's method1997Journal of natural products, Aug, Volume: 60, Issue:8
Structure and anti-acetylcholinesterase activity of 4 alpha-(hydroxymethyl)-4 alpha-demethylterritrem B.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID262754Anticholinesterase activity against human erythrocyte AChE2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
AID589524Selectivity index, ratio of IC50 for human erythrocytes recombinant AChE to IC50 for human plasmatic BChE2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
AID1140640Inhibition of human recombinant AchE using acetylthiocholine iodide as substrate incubated for 5 mins prior to substrate addition measured after 5 mins by Ellman method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
AID386742Selectivity ratio of IC50 for electric eel AchE to IC50 for human plasma BuchE2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.
AID551380Selectivity index, ratio of IC50 for human recombinant BChE to IC50 for human recombinant AChE2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.
AID262756Selectivity for AChE over BChE2006Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (131)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (25.19)18.7374
1990's33 (25.19)18.2507
2000's42 (32.06)29.6817
2010's22 (16.79)24.3611
2020's1 (0.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.49 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other134 (99.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]